CRYO-CELL International, Inc. (CCEL) Director Arthur Ellis Buys 2,975 Shares
CRYO-CELL International, Inc. (OTCMKTS:CCEL) Director Arthur Ellis bought 2,975 shares of the company’s stock in a transaction that occurred on Thursday, August 30th. The shares were bought at an average price of $7.93 per share, with a total value of $23,591.75. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Arthur Ellis also recently made the following trade(s):
- On Friday, August 24th, Arthur Ellis bought 40 shares of CRYO-CELL International stock. The shares were bought at an average price of $8.00 per share, with a total value of $320.00.
- On Tuesday, August 21st, Arthur Ellis bought 2,050 shares of CRYO-CELL International stock. The shares were bought at an average price of $8.04 per share, with a total value of $16,482.00.
Shares of CCEL stock opened at $7.91 on Wednesday. CRYO-CELL International, Inc. has a 1-year low of $6.50 and a 1-year high of $9.98. The company has a debt-to-equity ratio of -0.31, a current ratio of 1.02 and a quick ratio of 0.99. The stock has a market cap of $65.24 million, a P/E ratio of 25.55 and a beta of -0.15.
CRYO-CELL International Company Profile
Cryo-Cell International, Inc engages in cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, kidney, ALS, wound healing, and auto-immune diseases.
Recommended Story: Short Selling Stocks, A Beginner’s Guide
Receive News & Ratings for CRYO-CELL International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRYO-CELL International and related companies with MarketBeat.com's FREE daily email newsletter.